Yes, he typically writes and focuses on large pharma drugs and pipelines. I guess the thought is that they will license or partner with big pharma most of the time before coming to market and then he will/would include in his articles. There were several CYDY comments, so hopefully you are correct in that he is doing more DD before responding (he typically seems to provide informed responses).